Welcome to our dedicated page for Zentek news (Ticker: ZTEK), a resource for investors and traders seeking the latest updates and insights on Zentek stock.
Zentek Ltd. develops and commercializes graphene-enabled and advanced material technologies through platforms that include ZenGUARD™, Albany Graphite and Triera. Company developments center on ZenGUARD™ enhanced air filters and related regulatory classification, commercialization pathways and HVAC supply-chain opportunities.
Recurring updates also cover the Albany Graphite Project in Ontario, including technical studies, environmental and social baseline work, market analysis and high-purity graphite positioning for nuclear, defence, battery and industrial markets. Triera Biosciences updates focus on aptamer discovery, biosensor enablement, machine-learning classification and infectious-disease applications, alongside material agreements, capital-structure disclosure, governance matters and operating results.
Zentek (NASDAQ:ZTEK) announced that its ZenGUARD™ Enhanced Air Filters have been added to Innovative Solutions Canada's Pathway to Commercialization source list.
This makes Zentek an exclusive PTC supplier of this type of innovation to the Government of Canada for three years, enabling direct procurement by all federal departments and agencies, following National Research Council validation of performance and energy impact.
Zentek (NASDAQ: ZTEK) received a revised Health Canada classification that ZenGUARD™ Enhanced Air Filters are exempt from the Pest Control Products Act because they operate via a mechanical mode of action. The product is now available for commercial orders in Canada and Zentek is pursuing federal procurement, licensing, and sales of ZenGUARD™-enhanced filter media. ZenGUARD™ holds an issued Canadian patent (granted 2022; term to 2041) and has independent ASHRAE 52.2 testing showing MERV 9 performance with pressure drop equivalent to uncoated filters.
Zentek (NASDAQ: ZTEK) said Albany Graphite has engaged ERM to run a Year Two environmental and social baseline program at the Albany Graphite Project, integrating Constance Lake First Nation into every 2026 field campaign. The plan scopes twelve baseline disciplines and runs in parallel with a Preliminary Economic Assessment targeted for Summer 2026. The program builds on 2019 baseline work and highlights bench-scale production of 5N+ (99.9992% Cg) graphite from Albany feedstock disclosed Sept 22, 2025.
Zentek (NASDAQ: ZTEK) subsidiary Albany Graphite executed an agreement with AETC to produce certified 4N, 4N+ and 5N+ graphite samples and deliver process engineering inputs for Micon's PEA.
AETC will supply Certificates of Analysis for samples (initial 1.5 kg per grade in May 2026; full CoAs by July 2026) and deliver a conceptual, multi‑phase purification plant design sized to 30,000 TPA, with engineering deliverables due June 2026 to align with the PEA timeline.
Zentek (NASDAQ: ZTEK) subsidiary Albany Graphite engaged AppEco to produce an independent market research and economic analysis for the Albany Graphite Project near Hearst, Ontario.
Deliverables include a grade-specific price deck, 5‑ and 10‑year forecasts, North American/allied demand quantification, supply positioning versus Western pipelines, and valuation of 18 recoverable critical minerals from FBR scrubber exhaust. Bench-scale production of 5N+ graphite (99.9992 wt.% Cg) using a chlorine-free FBR process is cited as central to the study feeding into a PEA due this summer.
Triera Biosciences (ZTEK) completed an Innovative Solutions Canada program and has begun an Ontario Centres of Innovation Collaborate 2 Commercialize agreement to advance its aptamer platform toward seasonal influenza candidates. The OCI C2C project budget is approximately $300,000 with matched cash contributions from OCI and Zentek.
Triera selected an H5N1-binding aptamer in ~7 weeks and will apply multivalent aptamer engineering to H1N1, H3N2 and expanded strains, with workstreams including dose-finding, PK/PD modeling and initiation of GLP-style toxicology and immunogenicity studies.
Zentek (NASDAQ: ZTEK) subsidiary Albany Graphite engaged Micon to complete a new NI 43-101 Preliminary Economic Assessment (PEA) for the Albany Graphite Project near Hearst, Ontario, expected this summer (2026).
Micon will evaluate a tested 5N+ thermal purification route (99.9992% Cg from 86% flotation concentrate), update the Mineral Resource Estimate, produce PEA-level capex/opex estimates, and analyze economic sensitivities and environmental considerations.
Zentek (NASDAQ: ZTEK) engaged ICP Securities to provide automated market-making using its proprietary ICP Premium® algorithm, effective April 1, 2026. The agreement has an Initial Term of four months with automatic monthly renewals and a monthly fee of C$7,500 plus taxes. The engagement is subject to TSX Venture Exchange approval.
The arrangement includes no equity or performance-based pay, allows ICP and its clients to acquire securities, and aims to improve liquidity and quote quality for shareholders.
Triera Biosciences (NASDAQ:ZTEK) is launching contract research organization services for custom aptamer discovery, biosensor enablement, and ML classification support on March 25, 2026.
Built on an exclusive 20-year McMaster University license, Triera offers integrated SELEX aptamer development, biosensor integration, and optional ML signal classification targeting infectious disease and oncology diagnostics across North America and Europe.
Zentek (NASDAQ:ZTEK) won a favorable judgment in Ontario Superior Court on March 12, 2026, dismissing substantially all claims in companion litigation tied to the 2018 removal of founder Aubrey Eveleigh.
The Court denied monetary claims originally exceeding $6 million, refused cancellation of 4.5 million founder shares, and found relevant statements factually accurate.